IQV - AI Takes The Spotlight During HQ Visit; Mgmt Sees Disconnect Between Valuation & Operational Reality

Research evidence excerpt

IQV - AI Takes The Spotlight During HQ Visit; Mgmt Sees Disconnect Between Valuation & Operational Reality

anies. It also differentiated its offerings

from generic horizontal AI models, emphasizing that its solutions are purpose-built for healthcare and incorporate

domain-specific regulatory and compliance considerations.

Truist Securities Commentary: Based on our conversations with industry stakeholders, we understand that IQVIA is

pursuing three primary monetization pathways for its AI capabilities. First, AI is embedded within its FSO offering,

where it enhances efficiency and differentiation without being sold as a standalone product. Second, the company is

extending AI agents into functional service provider (FSP) relationships, enabling modular deployment tailored to

specific client functions such as data management. Third, IQVIA is offering bespoke consulting services, helping large

pharma clients design and build custom AI agents within their own environments. Together, these models expand AI

monetization across both services and technology layers. Separately, IQVIA is actively evaluating multiple pricing

approaches, including per-seat, usage-based, token-linked, and tiered subscription models.

AI Platform Risk, Data Ownership, and Healthcare-Specific Barriers

On the topic of Anthropic (private) and potential disruption risks, IQVIA reiterated that it has not lost any business to

Claude or other AI solutions and noted that it has, in fact, gained business on the commercial side through the sale of

AI agents. The company argued that healthcare is fundamentally different from legal or other data-rich industries

because the relevant data are not widely accessible. AI models require high-quality “fuel,” and IQVIA emphasized that